TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

TROPION-Lung12 Trial Initiation: The TROPION-Lung12 phase 3 trial has begun, evaluating the safety and efficacy of DATROWAY (datopotamab deruxtecan) combined with rilvegostomig or as monotherapy for patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after surgery, targeting ctDNA-positive individuals or those with high-risk features.

Need for Novel Treatment Options: Current treatment for stage 1 NSCLC often involves observation post-surgery, but up to 40% may relapse; thus, the trial aims to explore new strategies for identifying high-risk patients and providing effective adjuvant therapies to reduce recurrence rates.